“SHOCKING REVELATION: COVID-19 Vaccines Linked to Rare Eye Issues! What You NEED to Know – Exclusive MHRA Report Exposed!”
In December 2020, the US Food and Drug Administration granted emergency use authorization for the first COVID-19 vaccine, including BNT162b2 (Pfizer/BioNTech SE) and mRNA-1273 (Moderna Therapeutics). In January 2021, the European Medicines Agency authorized ChAdOx1 nCoV-19 (Oxford-AstraZeneca).
Vaccine-related uveitis has been reported with various vaccines, including those for hepatitis A and B, influenza, HPV, MMR, varicella, BCG, Neisseria meningitides, and yellow fever. Ocular inflammatory events, including those following COVID-19 vaccination, have been reported, with hypothesized mechanisms including molecular mimicry and hypersensitivity reactions. While a study found no association between COVID-19 vaccination and non-infectious uveitis, other ocular inflammatory events like scleritis and optic neuritis have been reported.
COVID-19 vaccine
The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK oversees drug safety. The Yellow Card System, part of pharmacovigilance, allows healthcare practitioners to voluntarily report adverse drug reactions. Yellow Card reports indicate suspected adverse drug reactions, not firm evidence of causation.
To address the evidence gap on ocular inflammatory events post-COVID-19 vaccine, this study analyzes spontaneous reports to the Yellow Card System in the UK. The MHRA provided data on new suspected adverse inflammatory ocular reactions from January 1, 2021, to September 28, 2022. The analysis includes patient demographics, medical characteristics, and outcomes.
Results show 125 reports associated withCOVID-19 vaccine Pfizer BioNTech, 154 with COVID-19 AstraZeneca, and 21 with COVID-19 Moderna. The calculated prevalence of ocular inflammatory events following vaccination was 6.6 per million individuals. Symptoms included reduced vision, floaters, eye pain, photophobia, and redness. Anterior uveitis was the most common phenotype (58.3%), followed by optic neuritis (39.3%). Resolution occurred in 52.3%.
The analysis considers the onset time, medical history, and prior conditions. The data support that ocular inflammatory events post-COVID-19 vaccination are rare. The Yellow Card System, a robust post-marketing surveillance tool, aids in identifying and evaluating adverse events, contributing to drug safety.
